Adverse drug reactions of intravesical bacillus Calmette–Guérin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder

Background: We examined the incidence and severity of adverse drug reactions following intravesical bacillus Calmette–Guérin (BCG) instillation for superficial bladder cancer including carcinoma in situ. We investigated the relationship between adverse drug reactions and patient background to clarify risk factors for the development of adverse drug reactions.

[1]  T. Uchida,et al.  Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low‐dose bacillus Calmette‐Guérin for superficial bladder cancer recurrence , 2003, International journal of urology : official journal of the Japanese Urological Association.

[2]  R. Sylvester,et al.  Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. , 2001, The Journal of urology.

[3]  J. Patard,et al.  Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer. , 2001, Urology.

[4]  D. Lamm.  Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  T. Lebret,et al.  Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. , 2000, The Journal of urology.

[6]  D. Chopin,et al.  BCG Intravesical Instillations: Recommendations for Side-Effects Management , 1999, European Urology.

[7]  D. Lamm,et al.  INTRAVESICAL CHEMOTHERAPY AND IMMUNOTHERAPY: HOW DO WE ASSESS THEIR EFFECTIVENESS AND WHAT ARE THEIR LIMITATIONS AND USES? , 1995, International journal of urology : official journal of the Japanese Urological Association.

[8]  A. P. M. Meijden.  Practical approaches to the prevention and treatment of adverse reactions to BCG. , 1995 .

[9]  A. van der Meijden.  Practical approaches to the prevention and treatment of adverse reactions to BCG. , 1995, European urology.

[10]  O. Nativ,et al.  The influence of patient positioning on the hemodynamic changes in TURP patients with severe coronary disease. , 1995, European urology.

[11]  F M Debruyne,et al.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. , 1992, The Journal of urology.

[12]  J. Dehaven,et al.  Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guerin toxicity. , 1992, The Journal of urology.

[13]  P. Scardino,et al.  A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. , 1991, The New England journal of medicine.

[14]  P. Bassi,et al.  A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? , 1991, The Journal of urology.

[15]  W. Whitmore,et al.  Toxicity of intravesical BCG and its management in patients with superficial bladder tumors , 1987, Cancer.